Cargando…
A Bisphosphonate With a Low Hydroxyapatite Binding Affinity Prevents Bone Loss in Mice After Ovariectomy and Reverses Rapidly With Treatment Cessation
Bisphosphonates (BPs) are a mainstay of osteoporosis treatment; however, concerns about bone health based on oversuppression of remodeling remain. Long‐term bone remodeling suppression adversely affects bone material properties with microdamage accumulation and reduced fracture toughness in animals...
Autores principales: | Coffman, Abigail A, Basta‐Pljakic, Jelena, Guerra, Rosa M, Ebetino, Frank H, Lundy, Mark W, Majeska, Robert J, Schaffler, Mitchell B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046044/ https://www.ncbi.nlm.nih.gov/pubmed/33869992 http://dx.doi.org/10.1002/jbm4.10476 |
Ejemplares similares
-
Reply to: A Bisphosphonate With a Low Hydroxyapatite Binding Affinity Prevents Bone Loss in Mice After Ovariectomy and Reverses Rapidly With Treatment Cessation
por: Coffman, Abigail A, et al.
Publicado: (2021) -
NE‐58025: A bisphosphonate with a low hydroxyapatite binding affinity
por: Pazianas, Michael
Publicado: (2021) -
Bisphosphonate use in the horse: what is good and what is not?
por: Mitchell, Alexis, et al.
Publicado: (2019) -
Growth Hormone Protects Against Ovariectomy-Induced Bone Loss in States of Low Circulating Insulin-like Growth Factor (IGF-1)*
por: Fritton, J Christopher, et al.
Publicado: (2010) -
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010)